Thomas Shrader analyst BTIG

Currently out of the existing stock ratings of Thomas Shrader, 96 are a BUY (89.72%), 11 are a HOLD (10.28%).

Thomas Shrader

Work Performance Price Targets & Ratings Chart

Analyst Thomas Shrader, currently employed at BTIG, carries an average stock price target met ratio of 45.47% that have a potential upside of 43.51% achieved within 199 days.

Thomas Shrader’s has documented 213 price targets and ratings displayed on 33 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BHVN, Biohaven Pharmaceutical Holding Co Ltd at 09-Jan-2024.

Wall Street Analyst Thomas Shrader

Analyst best performing recommendations are on SLN (SILENCE THERAPEUTICS PLC).
The best stock recommendation documented was for VRNA (VERONA PHARMA PLC ADR) at 12/20/2022. The price target of $26 was fulfilled within 10 days with a profit of $7.41 (39.86%) receiving and performance score of 39.86.

Average potential price target upside

BBIO BridgeBio Pharma BCAB Bioatla  BIIB Biogen CLVS Clovis Oncology ESPR Esperion Therapeutics GRTS Gritstone Oncology MNTA Momenta Pharmaceuticals PBYI Puma Biotechnology VYGR Voyager Therapeutics XON Precigen ACOR Acorda Therapeutics DNLI Denali Therapeutics NUVB Nuvation Bio INMB INmune Bio PGEN Precigen SGTX Sigilon Therapeutics  ABOS Acumen Pharmaceuticals SQZ Sqz Biotechnologies Co GANX Gain Therapeutics VRNA Verona Pharma PLC ADR ALEC Alector ATHA Athira Pharma  CELG Celgene MEIP MEI Pharma MGNX MacroGenics MRSN Mersana Therapeutics SELB Selecta Biosciences ANNX Annexon  DTIL Precision BioSciences STOK Stoke Therapeutics BHVN Biohaven Pharmaceutical Holding Co Ltd INO Inovio Pharmaceuticals SLN Silence Therapeutics PLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$43

$17.52 (68.76%)

$43

11 days ago
(25-Oct-2024)

6/24 (25%)

$19.16 (80.37%)

327

Buy

$46

$20.52 (80.53%)

$48

19 days ago
(17-Oct-2024)

12/17 (70.59%)

$19.81 (75.64%)

294

Buy

$44

$18.52 (72.68%)

$18

20 days ago
(16-Oct-2024)

3/4 (75%)

$17.66 (67.05%)

220

Buy

$70

$44.52 (174.73%)

$70

1 months 20 days ago
(16-Sep-2024)

1/8 (12.5%)

$43.81 (167.28%)

244

Buy

$42

$16.52 (64.84%)

$42

1 months 25 days ago
(11-Sep-2024)

2/5 (40%)

$14.01 (50.05%)

46

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Thomas Shrader?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?